News - Mineral Research
2012-05-10 09:50:59
The Food and Drug Administration (FDA) announced today that physicians should reassess patients with osteoporosis who are being treated with a class of drugs called bisphosphonates after three to five years of therapy to determine whether they should continue treatment.
2011-07-12 06:30:00
PHILADELPHIA, July 12, 2011 /PRNewswire/ -- Tarsa Therapeutics today reported progress in its two ongoing clinical development programs for its oral recombinant salmon calcitonin for the treatment and prevention of postmenopausal osteoporosis.